<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transthyretin (TTR), a Î²-strand rich tetrameric protein present in human serum and cerebrospinal fluid is involved in the transport of <z:chebi fb="4" ids="30660">thyroxine</z:chebi> and <z:chebi fb="1" ids="50211">retinol</z:chebi> binding protein:<z:chebi fb="1" ids="50211">retinol</z:chebi> complex (holo-RBP) </plain></SENT>
<SENT sid="1" pm="."><plain>TTR forms two T4 binding sites at the center of the dimer-dimer interface and contains holo-RBP binding sites on both faces of the tetramer </plain></SENT>
<SENT sid="2" pm="."><plain>Dissociation of TTR tetramers followed by misfolding and misassembly results in amyloid fibril formation, the causative agent of four <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Misfolding of <z:mp ids='MP_0002169'>wild type</z:mp> TTR in humans over 60 years of age is linked to a <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0002726" disease_type="Disease or Syndrome" abbrv="">amyloid disease</z:e> called senile systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Single point mutations enhance the amyloidogenicity of TTR, causing familial amyloid <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, familial amyloid <z:hpo ids='HP_0001271'>polyneuropathy</z:hpo>, and central <z:mp ids='MP_0008912'>nervous</z:mp> system selective <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>To date, nearly 200 X-ray crystal structures of TTR and their complexes have been solved </plain></SENT>
<SENT sid="6" pm="."><plain>They have provided potential insights into its structure-function relationships with molecular partners, and its interactions with small molecule ligands that inhibit tetramer destabilization and amyloid formation </plain></SENT>
<SENT sid="7" pm="."><plain>This review will focus on the key findings of the structural studies of TTR that provided atomic level description of its architecture, the mechanistic role of structural components involved in its function and misfolding, and the progress and limitations towards the design of selective inhibitors for TTR <z:e sem="disease" ids="C0002726" disease_type="Disease or Syndrome" abbrv="">amyloidoses</z:e> </plain></SENT>
</text></document>